| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 69.8 | 56.3 |
| Profit before tax | -22.4 | -28.4 |
| Net income | -22.6 | -22.6 |
| EPS (diluted, $ a share) | $-0.37 | $-0.38 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +24.1% |
|---|---|
| Operating margin | -33.7% |
10-Q filed with the SEC, NASDAQ: VNDA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Vanda Pharmaceuticals Inc.: key numbers
- Share price
- $3.81Close, Nov 16
- Market cap
- $230M
- Shares outstanding
- 60.47MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Vanda Pharmaceuticals Inc.
All →Vanda Pharmaceuticals Director Charles Cliff Duncan Buys $35.2K of Stock
Charles Cliff Duncan, Director, bought 9,250 shares of Vanda Pharmaceuticals Inc. at $3.80 to $3.82 a share (average $3.81) in 2 transactions, worth $35.2K in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 108,701 (+5.6%).
- Value
- $35.2K
- Shares
- 9,250
- Average price
- $3.81
- Role
- Director
- Holding change
- +5.6%
- Trade date
- Nov 4, 2026 to Nov 5, 2026
Vanda Pharmaceuticals Financial Results
Vanda Pharmaceuticals reported Q3 2026 total revenues of $69.8 million, a 24% year-over-year increase driven by Fanapt momentum and the commercial launch of NEREUS. Operating expenses decreased 18% sequentially to $93.3 million as major Phase III and launch-preparation activities began to conclude. The company is preparing for the Q4 2026 launch of BYSANTI and awaits an FDA decision on the Quimilza BLA in December.
- Term
- Q3 2026
“We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude.”
Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board
“Looking ahead, with the commercial launch of BYSANTI expected in the fourth quarter, the Quimilza BLA under FDA review with a December PDUFA date, and positive Phase III results supporting potential expansions for NEREUS in GLP-1-induced vomiting and HETLIOZ in Delayed Sleep-Wake Phase Disorder, we are focused on further moderating costs and driving revenue growth from our current portfolio and planned launches to support sustainable long-term value.”
Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board